BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fahmy UA, Fahmy O, Alhakamy NA. Optimized Icariin Cubosomes Exhibit Augmented Cytotoxicity against SKOV-3 Ovarian Cancer Cells. Pharmaceutics 2020;13:E20. [PMID: 33374293 DOI: 10.3390/pharmaceutics13010020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Fornasier M, Murgia S. Non-lamellar lipid liquid crystalline nanoparticles: A smart platform for nanomedicine applications. Front Soft Matter 2023;3. [DOI: 10.3389/frsfm.2023.1109508] [Reference Citation Analysis]
2 Deshmukh Shradha Suresh, Dr. Anil P. Dewani, Prof (Dr.) A. V. Chandewar. Cubosomes and its Pharmaceutical Application in Treatment of Cancer. IJARSCT 2023. [DOI: 10.48175/ijarsct-8628] [Reference Citation Analysis]
3 Vitoria Pupo Silvestrini A, Wender Debiasi B, Garcia Praça F, Vitoria Lopes Badra Bentley M. Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies. International Journal of Pharmaceutics 2022;628:122299. [DOI: 10.1016/j.ijpharm.2022.122299] [Reference Citation Analysis]
4 Fu Y, Liu H, Long M, Song L, Meng Z, Lin S, Zhang Y, Qin J. Icariin attenuates the tumor growth by targeting miR-1-3p/TNKS2/Wnt/β-catenin signaling axis in ovarian cancer. Front Oncol 2022;12:940926. [DOI: 10.3389/fonc.2022.940926] [Reference Citation Analysis]
5 Umar H, Wahab HA, Gazzali AM, Tahir H, Ahmad W. Cubosomes: Design, Development, and Tumor-Targeted Drug Delivery Applications. Polymers 2022;14:3118. [DOI: 10.3390/polym14153118] [Reference Citation Analysis]
6 Asfour HZ, Alhakamy NA, Fahmy UA, Ahmed OAA, Rizg WY, Felimban RI, Abdel-Naim AB, Abourehab MAS, Mansouri RA, Omar UM, Badr-Eldin SM. Zein-Stabilized Nanospheres as Nanocarriers for Boosting the Aphrodisiac Activity of Icariin: Response Surface Optimization and In Vivo Assessment. Pharmaceutics 2022;14:1279. [PMID: 35745852 DOI: 10.3390/pharmaceutics14061279] [Reference Citation Analysis]
7 Rawal SU, Patel BM, Patel MM. New Drug Delivery Systems Developed for Brain Targeting. Drugs 2022. [PMID: 35596879 DOI: 10.1007/s40265-022-01717-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Almoshari Y. Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review. Pharmaceutics 2022;14:600. [DOI: 10.3390/pharmaceutics14030600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Varghese R, Salvi S, Sood P, Kulkarni B, Kumar D. Cubosomes in cancer drug delivery: A review. Colloid and Interface Science Communications 2022;46:100561. [DOI: 10.1016/j.colcom.2021.100561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Patil SM, Sawant SS, Kunda NK. Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC). Int J Pharm 2021;607:121046. [PMID: 34450225 DOI: 10.1016/j.ijpharm.2021.121046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]